Literature DB >> 32956852

Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: A case series.

Hannah Martin1, Nora Amanda Barrett2, Tanya Laidlaw3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32956852      PMCID: PMC9255360          DOI: 10.1016/j.jaip.2020.09.007

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  6 in total

1.  Medical and surgical considerations in patients with Samter's triad.

Authors:  K Christopher McMains; Stilianos E Kountakis
Journal:  Am J Rhinol       Date:  2006 Nov-Dec

2.  A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease.

Authors:  Katherine L Tuttle; Kathleen M Buchheit; Tanya M Laidlaw; Katherine N Cahill
Journal:  J Allergy Clin Immunol Pract       Date:  2018-03-06

Review 3.  Mepolizumab in eosinophilic disorders.

Authors:  J Pablo Abonia; Philip E Putnam
Journal:  Expert Rev Clin Immunol       Date:  2011-07       Impact factor: 4.473

4.  Mepolizumab (Nucala) For Severe Eosinophilic Asthma.

Authors:  Min Sung Choy; Deepali Dixit; Mary Barna Bridgeman
Journal:  P T       Date:  2016-10

5.  Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature.

Authors:  Jessica P Rajan; Nathan E Wineinger; Donald D Stevenson; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2014-10-03       Impact factor: 10.793

6.  Aspirin-exacerbated respiratory disease: evaluation and management.

Authors:  Rachel U Lee; Donald D Stevenson
Journal:  Allergy Asthma Immunol Res       Date:  2010-08-20       Impact factor: 5.764

  6 in total
  1 in total

Review 1.  Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.

Authors:  Ryan Eid; Carol H Yan; Whitney Stevens; Taylor A Doherty; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2021-08       Impact factor: 14.290

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.